Mereo BioPharma Group plc
MREONext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for MREO. That does not mean none is planned.
Get an email about MREO's next catalysts
Track Mereo BioPharma Group (MREO) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
1 upcoming, 0 past
MREO Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.01 | FQ end Sep/2026 | Call: tbd
Market Overview
Stock performance and key metrics
Setrusumab
Osteogenesis Imperfecta
Alvelestat oral tablet - dose 1
Alpha 1-Antitrypsin Deficiency
Etigilimab
Solid Tumor, Adult
BGS649
Hypogonadotropic Hypogonadism
Active treatment with a high dose of BGS649
Endometriosis
BPS804
Osteopenia
Alvelestat
Covid19
Alvelestat (MPH966)
Alpha-1 Antitrypsin Deficiency (AATD)
Active treatment with a low dose of BGS649
Endometriosis
BCT197
Pulmonary Disease, Chronic Obstructive
Alvelestat oral tablet - dose 2
Alpha 1-Antitrypsin Deficiency
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Setrusumab | Phase 3 | Osteogenesis Imperfecta | - | - |
Alvelestat oral tablet - dose 1 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Etigilimab | Phase 2 | Solid Tumor, Adult | - | - |
BGS649 | Phase 2 | Hypogonadotropic Hypogonadism | - | - |
Active treatment with a high dose of BGS649 | Phase 2 | Endometriosis | - | - |
BPS804 | Phase 2 | Osteopenia | - | - |
Alvelestat | Phase 2 | Covid19 | - | - |
Alvelestat (MPH966) | Phase 2 | Alpha-1 Antitrypsin Deficiency (AATD) | - | - |
Active treatment with a low dose of BGS649 | Phase 2 | Endometriosis | - | - |
BCT197 | Phase 2 | Pulmonary Disease, Chronic Obstructive | - | - |
Alvelestat oral tablet - dose 2 | Phase 2 | Alpha 1-Antitrypsin Deficiency | - | - |
Frequently asked questions
What is in Mereo BioPharma Group plc's drug pipeline?→
CatalystAlert tracks 11 drug candidates in Mereo BioPharma Group plc's (MREO) pipeline across Phase 3, Phase 2. Its lead program is Setrusumab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Mereo BioPharma Group plc's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Mereo BioPharma Group plc (MREO) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track MREO biotech catalysts?→
Add MREO to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Mereo BioPharma Group plc's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.